Anal Cancer
If it’s your first time on this website, please read the disclaimer section.
May 18 – May 25, 2026
Bone-sparing chemoradiotherapy for anal cancer - Results of a phase II trial by the Danish Anal Cancer Group - The DACG II (NCT05385250).
RADIOTHER ONCOL · Q1 JOURNAL - RANK #22/212
This multicenter phase II trial investigated whether bone-sparing chemoradiotherapy could reduce pelvic insufficiency fracture (PIF) rates in patients with localized anal cancer. Patients prospectively received either standard or optimized bone-sparing radiotherapy plans, with toxicity tracked at baseline, during treatment, and at one-year follow-up, using bone-specific MRI as the primary outcome measure. Of 100 enrolled patients, 97% completed radiotherapy and chemotherapy, and the one-year PIF rate was 27.8%, markedly lower than historic rates of 50%. The study concluded bone-sparing radiotherapy significantly reduced PIF rates without affecting other organ toxicity or target coverage.
10.1016/j.radonc.2026.111605
May 04 – May 11, 2026
Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
The POD1UM-303/InterAACT-2 trial evaluated retifanlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel as first-line therapy for advanced/metastatic squamous cell carcinoma of the anal canal. This double-blind, phase 3 study randomized 308 patients, with primary endpoints of progression-free survival and overall survival. The final results demonstrated significant benefits for the retifanlimab combination, with improved PFS (HR 0.62, 95% CI 0.47–0.81, p=0.0002) and OS (HR 0.75, 95% CI 0.55–1.01, p=0.0305), including median OS of 32.8 vs. 22.2 months. These findings suggest the combination is a new therapeutic standard for inoperable, locally recurrent, or metastatic squamous anal cancer.
10.1016/j.annonc.2026.04.016
Apr 20 – Apr 27, 2026
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.
EUR J CANCER · Q1 JOURNAL - RANK #45/326
This phase 1, open-label, dose-escalation trial evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of OSE-279, an anti-PD-1 monoclonal antibody, in 20 patients with advanced solid tumors. Patients received intravenous OSE-279 at 100 mg q3w, 300 mg q3w, or 600 mg q6w. Key findings included two recommended phase 2 doses (300 mg q3w, 600 mg q6w), linear PK with >80% receptor occupancy, and durable responses: 1 complete response, 4 partial responses, and 7 stable disease, with response duration ranging from 6.8 to 18.4 months. The authors concluded OSE-279 monotherapy is well tolerated and shows durable antitumor activity, with the trial continuing in combination with a therapeutic cancer vaccine.
10.1016/j.ejca.2026.116729